Description

Royalty Pharma’s $3.45 Billion Outlook — Can R&D Co-Funding Supercharge Growth?

Royalty Pharma PLC reported its financial results for the first quarter of 2026, reflecting continued growth and expansion of its biopharma royalty portfolio. The company delivered a 10% increase in portfolio receipts and a 13% rise in royalty receipts, which form its recurring cash flow base. This growth was underpinned by the strength and diversification of its portfolio, alongside ongoing capital deployment exceeding $500 million, including acquisitions of royalty interests in therapies such as Jazz and BeOne’s Ziihera and increased investments in Revolution Medicines’ daraxonrasib. Royalty Pharma maintained robust returns, with a return on invested capital around 14% and return on invested equity near 20%. The company emphasized its evolving capital allocation strategy, increasingly incorporating innovative R&D co-funding deals with global biopharma partners such as Johnson & Johnson and Teva. These agreements provide mutual benefits by sharing development risks and offer Royalty Pharma access to potentially transformative therapies.